According to the European Medicines Agency, brand name xxx originating from Europe is manufactured at the following site(s):
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
GermanyGlaxo Wellcome, S.A.
Avda. Extremadura, 3
09400 Aranda De Duero, Burgos
SpainNovartis Farmacéutica S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Information about Votrient (Pazopanib)
Votrient is an oral medication that contains pazopanib, a tyrosine kinase inhibitor designed to treat specific types of cancer. Pazopanib works by blocking specific proteins that are involved in the growth of cancer cells and the formation of blood vessels that supply tumors. This helps slow or halt the growth of cancer.
Votrient is primarily used for the treatment of advanced kidney cancer (renal cell carcinoma) and soft tissue sarcoma in patients who have not responded to previous treatments.
Product Highlights
Votrient is primarily used for the treatment of advanced RCC, a type of kidney cancer that has spread to other parts of the body.
It is also indicated for the treatment of certain types of soft tissue sarcomas in patients who have already been treated with chemotherapy.
It is prescribed for patients whose cancers are inoperable or have spread to distant parts of the body.
Key Ingredient
Pazopanib
Key Benefits
Pazopanib helps slow the growth of cancer cells and reduces the blood supply to tumors by inhibiting angiogenesis.
In patients with advanced RCC, Votrient can help improve progression-free survival, meaning it helps patients live longer without their cancer worsening.
Taken once daily, making it more convenient compared to other cancer treatments that may require more frequent administration.
As a targeted therapy, pazopanib selectively affects cancer cells and blood vessels, causing less harm to healthy cells compared to traditional chemotherapy.
Direction of Use
Votrient is typically taken as a once-daily oral tablet. The usual dose for renal cell carcinoma is 800 mg per day.
Votrient should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal, to enhance absorption and minimize the risk of gastrointestinal side effects.
Take the medication at the same time every day and swallow the tablet whole. Do not crush or chew the tablet.
Recommended Dose Reductions of VOTRIENT for Adverse Reactions
Dose reduction
For renal cell carcinoma
For soft tissue sarcoma
First
400 mg orally once daily
600 mg orally once daily
Second
200 mg orally once daily
400 mg orally once daily
Discontinue VOTRIENT permanently in patients who cannot tolerate the second dose reduction.
Safety Concerns
Pazopanib can cause liver damage, so liver function should be monitored regularly with blood tests, especially during the first 4-6 weeks of treatment.
It may increase the risk of high blood pressure, heart failure, or other cardiovascular problems. Blood pressure should be monitored regularly, and patients may need antihypertensive treatment.
Nausea, vomiting, diarrhea, and changes in appetite are common side effects. These should be managed with supportive care.
There is an increased risk of bleeding, including serious events such as gastrointestinal bleeding. Monitor for signs of bleeding, including blood in stools or vomit.
Pazopanib can affect kidney function. Kidney function tests should be conducted before and during treatment.
A common side effect, fatigue can significantly affect the patient’s quality of life.
Pazopanib can cause skin problems such as rashes, hand-foot syndrome (redness, swelling, and pain in the palms of the hands and soles of the feet), and changes in skin pigmentation.
Avoid Votrient (Pazopanib) If
You are allergic to pazopanib or any of the ingredients in Votrient.
You have severe liver problems, such as cirrhosis or liver failure.
You have a history of heart disease, including heart failure, or uncontrolled high blood pressure.
